Monoclonal Antibodies

The ENG monoclonal antibody is produced by employing a synthesized peptide derived from human CD105 protein as an immunogen. B cells are isolated from the immunized mouse and then fused with myeloma cells. This results in hybridoma cells that are subsequently screened to identify the cell line producing the ENG antibody. The CD105 monoclonal antibody is affinity-purified from mouse ascites through affinity-chromatography using a specific immunogen. The purified antibody is an unconjugated IgG2b, Kappa. It demonstrates the ability to recognize human ENG protein in ELISA and IHC applications.

Endoglin (ENG), also known as CD105, is primarily expressed on endothelial cells and plays a critical role in angiogenesis. Endoglin functions as a co-receptor for TGF-β1 and TGF-β3, binding to these cytokines and enhancing their signaling activity in endothelial cells. It also interacts with other cell surface receptors, such as integrins, and extracellular matrix proteins, facilitating cell adhesion and migration. Furthermore, Endoglin has been shown to regulate vascular permeability, participate in vascular inflammation, and modulate cellular responses to oxidative stress.

This KRT1 monoclonal antibody is produced by immunizing a mouse with a synthesized peptide derived from the human KRT1 protein. B cells are isolated from the mouse spleen and fused with myeloma cells to generate hybridoma cells. These hybridoma cells are screened for the production of the KRT1 antibody. The selected hybridoma cells are cultured in the mouse abdominal cavity, and the KRT1 monoclonal antibody is purified from the mouse ascites by affinity chromatography using a specific immunogen.

This KRT1 monoclonal antibody is an unconjugated IgG1, Kappa antibody, suitable for recognizing the human KRT1 protein in ELISA and IHC applications.

KRT1 is specifically expressed in the cornified layer of the epidermis and forms a network of intermediate filaments. This network provides mechanical strength and resilience to the skin. KRT1 is also involved in the regulation of cell migration, differentiation, and apoptosis. Mutations in the KRT1 gene have been linked to various skin disorders, including epidermolytic hyperkeratosis and palmoplantar keratoderma.

The KRT14 monoclonal antibody is produced through a multi-step process. Mice are immunized with a synthesized peptide derived from human KRT14, stimulating the production of antibodies. B cells from the immunized mice's spleens are then fused with myeloma cells to create hybridomas, which are further screened to select those producing antibodies specific to KRT14. These selected hybridomas are cultured in the mouse's abdominal cavity, and the KRT14 monoclonal antibodies are purified from the resulting ascites fluid using affinity chromatography with a specific immunogen. This purified mouse monoclonal antibody specifically recognizes human KRT14 protein and is suitable for use in ELISA and IHC applications.

KRT14 is specifically expressed in the basal cells of stratified epithelia, such as the epidermis of the skin. Its primary function is to provide mechanical strength to these epithelial cells, protecting them from mechanical stress. KRT14 also plays a role in cell signaling, adhesion, and migration. Mutations in the KRT14 gene have been linked to various skin disorders, including epidermolysis bullosa simplex, a condition characterized by blistering and erosion of the skin.

This mouse monoclonal antibody is generated through a hybridoma technology. Briefly, mice were immunized with a synthesized peptide derived from human KRT16. Subsequently, B cells were isolated from the mouse spleen and fused with myeloma cells to create hybridomas. These hybridomas were then screened to select clones that produce KRT16 antibodies. The chosen hybridomas were injected into the mouse abdominal cavity for culture, and the KRT16 monoclonal antibody was affinity-purified from mouse ascites using a specific immunogen. This process yields a monoclonal antibody that specifically binds to human KRT16 protein in ELISA and IHC applications.

KRT16, a type I intermediate filament protein, primarily contributes to structural support in hair follicles, nails, and the oral epithelium. It forms heterodimers with other type I and type II keratin proteins, ultimately assembling into intermediate filaments crucial for maintaining the structural integrity of epithelial cells. Mutations in the KRT16 gene are known to be associated with various skin and nail disorders, including pachyonychia congenita.

The KRT17 monoclonal antibody is produced by immunizing mice with a synthetic peptide derived from human KRT17. B cells are isolated from the mouse spleen and fused with myeloma cells to generate hybridomas. These hybridomas are screened for the production of KRT17 antibodies. Selected hybridomas are cultured in the mouse abdominal cavity, and the KRT17 monoclonal antibodies are purified using affinity chromatography with a specific immunogen. The resulting purified KRT17 mouse monoclonal antibody exhibits high specificity, reacting exclusively with human KRT17 protein in ELISA and IHC applications.

KRT17, a type I intermediate filament protein, is essential for maintaining the structural integrity of epithelial cells. Specifically, KRT17 is expressed in the basal layer of stratified epithelia and plays a crucial role in cell adhesion, migration, and differentiation. KRT17 has also been implicated in wound healing, cancer metastasis, and the regulation of the hair cycle.